Tackling the toughest cancers.
Penetration of anti-cancer agents into and throughout solid tumours is widely recognised as presenting a major limitation to their effectiveness.
SonoTran® is being developed to provide a step-change in the therapeutic index of anti-cancer agents without the development costs or delays associated with drug reformulation. SonoTran® is designed to increase the dose and distribution of anti-cancer agents within solid tumours, thereby increasing the efficacy and/or reducing the toxicity of these agents across the majority of the most challenging solid tumour cancers.
Nicholas AdamsChief Business Officer
Dr Christian CovielloChief Technology Officer & Co-Founder
Dr. Marianna Lalla MD PhD MPH CCT (PharmMed., PeadSurg.)Chief Medical Officer
Dr Allison Jeynes MD, FFPM (UK)Non-Executive Chair
Andrew Mullen MBAChief Operating Officer
Gene SaragneseNon-Executive Director
David PrestonFinance Director
Dr Cliff RoweDevelopment Director
Glyn Edwards MBEExecutive Director
Dr Matthew FrohnNon-Executive Director
George RobinsonBoard Member
Prof. Constantin Coussios OBE FREngNon-Executive Director & Co-Founder
Prof. Fergus Gleeson FRCP FRCRClinical Advisor
Prof. Hardev Pandha MB ChB (Birm) FRACP FRCP PhD CSST (Medical Oncology)Clinical Advisor
Mr Robert JonesClinical Advisor
Dr Colin StoryCo-Founder
Prof. Robert CarlisleCo-Founder
OxSonics was founded in 2013 to commercialise ground-breaking technological advances developed over more than ten years at the Biomedical Ultrasonics, Biotherapy and Biopharmaceuticals Laboratory (BUBBL) at the University of Oxford in the UK. BUBBL is an internationally-recognized centre of excellence in therapeutic ultrasound and drug delivery within the Oxford Institute of Biomedical Engineering.
Since 2013, OxSonics has built a world-leading multi-disciplinary product development and commercialisation team that have successfully developed the SonoTran® Platform as a scalable commercial-grade product. We work closely with both medical oncologists and oncology radiologists to ensure our products are directed at the specific patient groups that stand to benefit most but also that our products fit seamlessly into existing patient care pathways in an oncology ward setting.
Today, SonoTran® is being evaluated clinically and we’re working with multiple partners to tackle the toughest cancers, head on.